You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 5 Next »

Robert Malone (linkedin)

Robert Malone Experiences - from linked in, pasted below in case it gets removed

CEO, Analyst and Consultant: Proposal Development, Clinical Research, Vaccines and Biologics

RW Malone MD, LLCOct 2001 - Present · 20 yrs 4 mosMadison, VA

    • Proposal development, strategic leadership, partnership development, Consulting services in Government Contracting Consulting services in Commercial Intelligence and due diligence, FDA Phase I, II, and III clinical trials, protocol development and submission, and related regulatory submissions including pIND and IND.
      He has been involved in developing, designing, and providing oversight of approximately forty phase 1 clinical trials and twenty phase 2 clinical trials, as well as five phase 3 clinical trials. He has served as medical director/medical monitor on approximately forty phase 1 clinical trials, and on twenty phase 2 clinical trials, including those run at vaccine-focused Clinical Research Organizations. He has served as principal investigator on some of these. Currently working as a principal consultant for a CRO. Providing business development, proposal management, clinical development, regulatory and medical affairs support for pharmaceutical, vaccines-related and biologics companies.



    • RW Malone MD, LLC
      RW Malone MD LLC is a customer-focused premier consultancy and analytics group, specializing in analytics for the bio-sector, commercial intelligence, opportunity capture, clinical trials and proposal development.

      • CEO

        Atheric Pharmaceutical LLCFeb 2016 - Jan 2017 · 1 yrScottsville, VA

          • CEO and co-founder of Atheric Pharmaceutical LLC. A biopharmaceutical company focused on the rapid development and commercialization of repurposed drugs to prevent and treat Flavivirus disease based (e.g., Nile virus, Dengue Fever and Zika virus) neurological disorders (e.g., Guillain-Barre Syndrome, microcephaly). Atheric™ is committed to providing broad-spectrum medical countermeasures for Zika and other neglected tropical diseases for humankind.
            Zika outbreak medical countermeasure (MCM) strategies have been identified, with the most promising

            Atheric has anti-viral drugs, safe for humans in all three trimesters of pregnancy, for use in protecting against the Zika Virus infection; to prevent development of Zika Virus fetal syndrome and GBS. Provisional patents covering the used of these compounds for Zika and other Flaviviruses have been filed with the US Patent and Trademark Office. Clinical trials to determine correct dosing and proprietary formulations appropriate for the indicated therapies (including prophylactic use) are being rapidly developed. Regulatory discussions with FDA have been initiated.

      • Medical Director, Vaccines

        BeardsworthMar 2010 - Apr 2013 · 3 yrs 2 mos

          • Business development, medical monitoring, proposal management, strategic consulting. This retainer position was contracted under RW Malone MD, LLC.

      • Adjunct Associate Professor

        Kennesaw State University2009 - 2013 · 4 yrs 1 moKennesaw, GA

          • Associate Professor in Biotechnology

      • Editor in Chief

        Journal of Immune Based Therapies and VaccinesFeb 2009 - Jan 2011 · 2 yrs

          • Journal of Immune Based Therapies and Vaccines is an Open Access, peer-reviewed, online journal dedicated to all aspects of therapeutic and prophylactic applications of immunology.

            Journal of Immune Based Therapies and Vaccines aims to advance the understanding and application of specific immunological mechanisms, immune correlates of protection and activity, strategic regulatory and clinical development considerations, and other issues relating to accelerating the advanced development and licensure of efficacious vaccines and immune based therapies (IBTs). The areas of vaccines and IBTs encompass many different disciplines, including infectious diseases, transplantation, cancer, allergic diseases, and autoimmune diseases.

      • Medical Director, Vaccines

        AccelovanceOct 2008 - Oct 2009 · 1 yr 1 moMaryland

          • As a member of Accelovance’s Executive Management team, Dr. Malone combines entrepreneurial business talents and biotech industry expertise on a global scale to support the vision of the company. This retainer position was contracted under RW Malone MD, LLC

      • consultant

        PATH2008 - 2009 · 1 yr 1 mo

          • Consulting in Alternative delivery technologies, including clinical trials consulting and management in Brazil. This retainer position was contracted under RW Malone MD, LLC

      • Senior Director, Vaccines and Therapeutics

        EpiVaxDec 2007 - Oct 2008 · 11 mos

          • Part time service on retainer focused on product development and transition from pre-clinical to clinical development, Business planning and development, and proposal development.

      • Director, Clinical Development/Medical Affairs, Influenza

        Solvay Pharmaceuticals, Inc.Nov 2006 - Dec 2007 · 1 yr 2 mos

          • Responsibilities included leading an extended clinical team (both internal and CRO components), providing project and clinical trials management oversight, serving as primary author on clinical protocols, strategic documents including clinical development plans, all clinical documents required to support IND filing, generating and managing cost projections and budgetary oversight, providing strategic management and serving as a communication hub for clinical aspects of a 300M USD federal contract to develop and license a cell-based influenza vaccine.

      • Senior Medical Director

        Summit Drug Development ServicesOct 2005 - Oct 2006 · 1 yr 1 mo

          • Summit is a drug development services provider addressing due diligence assessments and strategic drug development planning to preparing regulatory submissions and implementing, monitoring, and analyzing clinical trials for its clients. While serving at Summit, Dr. Malone was the primary author of three pIND, two IND, an Appendix M submission and has served as proposal manager and primary author for a 129M USD federal contract submission focused on pandemic influenza.

      • Associate Director, Clinical Research

        Dynport Vaccine Company, LLCOct 2002 - Oct 2003 · 1 yr 1 mo

          • Dynport vaccine company (www.dynport.com) is a government contractor that holds the primary contract for advanced development of biodefense vaccines for the US Department of Defense.
            • Serving as liaison between product development teams and clinical research support group
            1. Preparation of planning documents and product development plans
            2. Identification of new technologies relevant to product development teams, facilitating integration of same in product development plans
            3. Preparing documents for clinical trials including investigator brochures
            4. Preparing proposal solicitations, technical review of subcontractor proposals
            • Serving as senior staff for technology watch program
            5. Technical review of potential subcontractors, new technologies
            6. Preparation of technical reviews for monthly in-house publication
            7. Assisting business development group in strategic evaluation and planning concerning new business opportunities

      • Chief of Laboratory Science and Director of Tissue Banking

        USUHS Dept of Surgery, Clinical Breast Care Program (CBCP)Sep 2000 - Sep 2001 · 1 yr 1 mo

          • • Worked closely with architect firm to design space, set-up laboratory facilities for the Clinical Breast Care Project, including new facilities design (tissue banking facilities, laboratory, animal rooms, animal surgical suite, office suites) at USUHS and Windber Medical Center, PA
            • Hired faculty, technicians, staff for CBCP at both sites, including writing and initiating job descriptions, job interviews, hiring decisions, set-up for re-locations
            • Laboratory Supervisor: Tissue banking immunology, cell culture, gene transfer, genetic vaccination research, animal research.

      • Assistant Professor

        University of Maryland, Baltimore School of Medicine, Dept. ofJan 1997 - Aug 2000 · 3 yrs 8 mos

          • Set-up and ran successful research laboratory in immunology (genetic vaccination) and gene transfer.

      • Assistant Professor , Pathology

        University of California, Davis Department of Medical Pathology,Oct 1993 - Jan 1997 · 3 yrs 4 mos

          • Director and Founder, Gene Therapy Program (pulmonary, dermal, heart, liver, mucosal and parenteral vaccines)

      • Research Fellow

        UC Davis Medical CenterJul 1992 - Sep 1993 · 1 yr 3 mos

          • • Succesful grant writing
            • Research in genetic (DNA) vaccination and gene transfer.
            • laboratory set-up

      • Scientist

        Vical1989 · Less than a year

          • Invented naked DNA and RNA delivery, DNA vaccine technology

      • Graduate Student

        Salk Institute1986 - 1989 · 3 yrs 1 mo

          • Pioneering work in mRNA structure, function, delivery, non-viral gene delivery

      • Foreman, Shingling crew

        Michael Charmichael ConstructionOct 1978 - Jan 1980 · 1 yr 4 mos

          • Leadership of construction crew of 3-4 contractors, assistance with design and implementation of unique private residence located in the Mission Canyon area of Santa Barbara. An on line video clip of the home can be found in the HGTV "Extreme Homes" video library at http://www.hgtv.com/videos/a-whale-of-a-house/3406.html


 (The Center Square) – The head of Indianapolis-based insurance company OneAmerica said the death rate is up a stunning 40% from pre-pandemic levels among working-age people.

“We are seeing, right now, the highest death rates we have seen in the history of this business – not just at OneAmerica,” the company’s CEO Scott Davison said during an online news conference this week. “The data is consistent across every player in that business.”

OneAmerica is a $100 billion insurance company that has had its headquarters in Indianapolis since 1877. The company has approximately 2,400 employees and sells life insurance, including group life insurance to employers in the state.

Davison said the increase in deaths represents “huge, huge numbers,” and that’s it’s not elderly people who are dying, but “primarily working-age people 18 to 64” who are the employees of companies that have group life insurance plans through OneAmerica.

“And what we saw just in third quarter, we’re seeing it continue into fourth quarter, is that death rates are up 40% over what they were pre-pandemic,” he said.

“Just to give you an idea of how bad that is, a three-sigma or a one-in-200-year catastrophe would be 10% increase over pre-pandemic,” he said. “So 40% is just unheard of.”

Davison was one of several business leaders who spoke during the virtual news conference on Dec. 30 that was organized by the Indiana Chamber of Commerce.

Most of the claims for deaths being filed are not classified as COVID-19 deaths, Davison said.

“What the data is showing to us is that the deaths that are being reported as COVID deaths greatly understate the actual death losses among working-age people from the pandemic. It may not all be COVID on their death certificate, but deaths are up just huge, huge numbers.”

He said at the same time, the company is seeing an “uptick” in disability claims, saying at first it was short-term disability claims, and now the increase is in long-term disability claims.

“For OneAmerica, we expect the costs of this are going to be well over $100 million, and this is our smallest business. So it’s having a huge impact on that,” he said.

He said the costs will be passed on to employers purchasing group life insurance policies, who will have to pay higher premiums.

The CDC weekly death counts, which reflect the information on death certificates and so have a lag of up to eight weeks or longer, show that for the week ending Nov. 6, there were far fewer deaths from COVID-19 in Indiana compared to a year ago – 195 verses 336 – but more deaths from other causes – 1,350 versus 1,319.

These deaths were for people of all ages, however, while the information referenced by Davison was for working-age people who are employees of businesses with group life insurance policies.

At the same news conference where Davison spoke, Brian Tabor, the president of the Indiana Hospital Association, said that hospitals across the state are being flooded with patients “with many different conditions,” saying “unfortunately, the average Hoosiers’ health has declined during the pandemic.”

In a follow-up call, he said he did not have a breakdown showing why so many people in the state are being hospitalized – for what conditions or ailments. But he said the extraordinarily high death rate quoted by Davison matched what hospitals in the state are seeing.

"What it confirmed for me is it bore out what we're seeing on the front end,..." he said.

The number of hospitalizations in the state is now higher than before the COVID-19 vaccine was introduced a year ago, and in fact is higher than it’s been in the past five years, Dr. Lindsay Weaver, Indiana’s chief medical officer, said at a news conference with Gov. Eric Holcomb on Wednesday.

Just 8.9% of ICU beds are available at hospitals in the state, a low for the year, and lower than at any time during the pandemic. But the majority of ICU beds are not taken up by COVID-19 patients – just 37% are, while 54% of the ICU beds are being occupied by people with other illnesses or conditions.

The state's online dashboard shows that the moving average of daily deaths from COVID-19 is less than half of what it was a year ago. At the pandemic's peak a year ago, 125 people died on one day – on Dec. 29, 2020. In the last three months, the highest number of deaths in one day was 58, on Dec. 13.

The Center Square

https://www.thecentersquare.com/indiana/indiana-life-insurance-ceo-says-deaths-are-up-40-among-people-ages-18-64/article_71473b12-6b1e-11ec-8641-5b2c06725e2c.html
  • No labels